Neurotherapeutics · 2023 · 11 citations · 56 references
Life SciencesMedicinal ChemistryNeuroscienceDementiaDrug DiscoveryNeurodegenerationAlzheimer DiseaseNeurodegenerative DiseasesNeurodegenerative DisordersProtein AggregationProtein Interaction DomainsTau PathologyAmyloid ToxicityAmyloid-beta-induced NeurotoxicityInhibitor ScreeningLead Compound OptimizationLead Compound ScreeningSh3 Domain InteractionsTau HyperphosphorylationTau-targeted Therapy
Alzheimer's disease (AD) is the leading cause of dementia and lacks highly effective treatments. Tau-based therapies hold promise. Tau reduction prevents amyloid-β-induced dysfunction in preclinical models of AD and also prevents amyloid-β-independent dysfunction in diverse disease models, especially those with network hyperexcitability, suggesting that strategies exploiting the mechanisms underlying Tau reduction may extend beyond AD. Tau binds several SH3 domain-containing proteins implicated in AD via its central proline-rich domain. We previously used a peptide inhibitor to demonstrate that blocking Tau interactions with SH3 domain-containing proteins ameliorates amyloid-β-induced dysfunction. Here, we identify a top hit from high-throughput screening for small molecules that inhibit Tau-FynSH3 interactions and describe its optimization with medicinal chemistry. The resulting lead compound is a potent cell-permeable Tau-SH3 interaction inhibitor that binds Tau and prevents amyloid-β-induced dysfunction, including network hyperexcitability. These data support the potential of using small molecule Tau-SH3 interaction inhibitors as a novel therapeutic approach to AD.
56
Development and testing of a general amber force field
Junmei Wang, Romain M. Wolf, James W. Caldwell et al. · Journal of Computational Chemistry · 2004 · 19.6K citations
The PyMOL Molecular Graphics System
Warren L. DeLano · Medical Entomology and Zoology · 2002 · 18.1K citations
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj-Linda B. Selenica, Milene L. Brownlow, Jeffy P. Jimenez et al. · Neurodegenerative Diseases · 2012 · 10.4K citations · Full text